Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhy combining these two medicines is more complicated than it sounds
The myth: combining both medicines produces faster or greater weight loss
The idea tends to circulate in forums and social media: if semaglutide loses you 15% body weight and tirzepatide loses you 20%, surely taking both gets you further, faster? It is an understandable leap, and it is wrong. Semaglutide acts on GLP-1 receptors. Tirzepatide acts on GLP-1 receptors too, plus a second receptor (GIP). Layering them does not add a third pathway; it saturates the same one while doubling the pharmacological load on your gastrointestinal system, your kidneys and your cardiovascular system. No clinical trial has investigated combination dosing for weight management. What the evidence does show is that the nausea, vomiting and gastric slowing these medicines already cause individually can become severe, and dehydration from compounded GI effects carries genuine risk. The NHS tirzepatide medicines page and the Mounjaro Summary of Product Characteristics are both clear that tirzepatide is taken as a standalone therapy.
If you have tried one and feel it is not working, that is a conversation worth having with a prescriber. The answer is usually an assessment of dose, timing, lifestyle factors or a switch, not an addition. Anyone asking whether you can mix tirzepatide and semaglutide will find the clinical reasoning against it follows exactly this logic.
What the head-to-head evidence actually says about choosing between them
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4mg over 72 weeks in adults with obesity and without diabetes. Tirzepatide produced a larger average weight reduction. That is the strongest direct comparison available, and NICE's appraisal of tirzepatide (TA1026) references indirect comparisons that point in the same direction. The gap narrows at the newer 7.2mg semaglutide maintenance dose, approved by the MHRA in April 2026, which reported around 20.7% average loss over 72 weeks in trials. If you are weighing up the options, our guide to choosing between semaglutide or tirzepatide walks through how those trial results translate into a real-world decision.
The table below summarises the key differences between the two licensed medicines as standalone treatments.
| Feature | Mounjaro (tirzepatide) | Wegovy (semaglutide injection) |
|---|---|---|
| Receptor targets | GLP-1 and GIP (dual agonist) | GLP-1 only |
| Delivery | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Average weight loss in trials | ~20–21% at 15mg (SURMOUNT-1, NEJM) | ~15% at 2.4mg (STEP 1, NEJM); ~20.7% at 7.2mg |
| UK licence for weight management | Yes (BMI ≥30, or ≥27 with a weight-related condition) | Yes (BMI ≥30, or ≥27 with a weight-related condition) |
| Oral option available? | No | Yes, Wegovy tablets (MHRA-approved June 2026) |
| Can be combined with the other? | No (not clinically appropriate | No) not clinically appropriate |
For a fuller side-by-side read, the Wegovy vs Mounjaro comparison on this site covers mechanism, eligibility and cost context in more detail.
What to do if you are switching from one to the other
Switching is a different question from stacking, and a legitimate one. Some people start on semaglutide and later ask about tirzepatide, or the reverse. There is a period where the first medicine needs to clear your system before the second begins, and dose selection at the start of the new treatment is a clinical judgement, not simply a continuation from where you left off. The page on moving to tirzepatide after semaglutide covers what that transition typically involves. Attempting an overlap without prescriber oversight is exactly the kind of scenario that produces the compounded side-effect risk described above, and our page on mixing semaglutide and tirzepatide explains in detail why that overlap period is clinically significant. It is also worth knowing that our prescribers review transfer patients' evidence before any dose or medicine change, that review exists precisely because these transitions need clinical thought, not guesswork.
If you are frustrated that one medicine is not delivering the results you expected, that frustration is fair. Plenty of people reach that point. The right next step is speaking to our team, not adjusting the combination yourself.
How a prescriber decides which medicine is right for you
This is where clinical assessment matters most. A prescriber weighs your medical history, any conditions that make one medicine preferable, medicines you already take, how you responded to a previous GLP-1 if you have used one, and your practical preferences, including whether an injection or a daily tablet option fits your life better. Neither medicine is categorically superior for every person. SURMOUNT-5 is a population average; your response will be shaped by factors that averages do not capture. People who want to understand what it would mean in practice to take semaglutide and tirzepatide together often find that reading through the clinical reasoning settles the question more clearly than any forum discussion.
Which suits you is a clinical decision our prescribers make with you, not something that can be settled by combining both and hoping for the best. If you want that conversation, starting with a free consultation is the straightforward first step. Our clinical team, led by our lead prescriber, reviews every consultation the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.